Chronic Myelogenous Leukemia Clinical Trials

180 clinical trials for Chronic Myelogenous Leukemia across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP — RECRUITING · PHASE2
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) — RECRUITING
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Asciminib Roll-over Study — RECRUITING · PHASE4
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• Methods of T Cell Depletion Trial (MoTD) — RECRUITING · PHASE2
• Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial — RECRUITING
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen — RECRUITING
• A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ASCIMINIB IN PEDIATRIC PARTICIPANTS NEWLY DIAGNOSED OR PREVIOUSLY TREATED WITH PHILADELPHIA POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (PH+ CML-CP) WITH OR WITHOUT KNOWN T315I MUTATION — RECRUITING · PHASE2
• ASCIMINIB, WITH OR WITHOUT DASATINIB COMBINATION, AS A 2ND-LINE THERAPY TO ADVANCE THE TREATMENT FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (ASC2ADVANCE) — RECRUITING
• Cord Blood Transplant in Adults With Blood Cancers — RECRUITING · PHASE2
• ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — RECRUITING · PHASE2
• TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia — RECRUITING · PHASE1
• A PHASE III, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF ORAL ASCIMINIB VERSUS INVESTIGATOR SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE — RECRUITING · PHASE3
• AN OPEN LABEL, MULTI-CENTER ASCIMINIB ROLL-OVER STUDY TO ASSESS LONG-TERM SAFETY IN PATIENTS WHO HAVE COMPLETED A NOVARTIS SPONSORED ASCIMINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT — RECRUITING
• PHASE 3 RANDOMIZED, CONTROLLED STUDY OF BLINATUMOMAB ALTERNATING WITH LOW-INTENSITY CHEMOTHERAPY VERSUS STANDARD OF CARE FOR OLDER ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH SAFETY RUN-IN (GOLDEN GATE STUDY) — RECRUITING · PHASE3
• Comparison of Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML — COMPLETED · PHASE3
• Study with ponatinib in patients with leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients — COMPLETED · PHASE2
• Safety And Efficacy Of Bosutinib — COMPLETED
• Administration of Donor T Cells With the Caspase-9 Suicide Gene — ACTIVE_NOT_RECRUITING · PHASE1
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases — TERMINATED · NA
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. — COMPLETED · PHASE2
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation — TERMINATED · PHASE3
• TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients — NOT_YET_RECRUITING · PHASE3
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide — ACTIVE_NOT_RECRUITING · PHASE2
• Asciminib Treatment Optimization in ≥ 3rd Line CML-CP — COMPLETED · PHASE3
• Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders — COMPLETED · NA
• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS — COMPLETED · PHASE3
• Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy — ACTIVE_NOT_RECRUITING · PHASE2
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine — COMPLETED · PHASE1
• Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia — COMPLETED · NA
• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell — COMPLETED · PHASE1
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP) — OTHER · PHASE2
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep — COMPLETED · PHASE2
• INCB018424 in Patients With Advanced Hematologic Malignancies — COMPLETED · PHASE2
• Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs — COMPLETED · PHASE3
• TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients — ACTIVE_NOT_RECRUITING · PHASE1
• A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia — NOT_YET_RECRUITING · PHASE1
• Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) — COMPLETED · PHASE2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) — COMPLETED · PHASE2
• Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) — NOT_YET_RECRUITING · PHASE1
• An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia — TERMINATED · PHASE1
• TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) — COMPLETED · PHASE3
• A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL — COMPLETED · PHASE1
• The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia Patients — OTHER
• Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study — COMPLETED · PHASE4

Refine this search